133 related articles for article (PubMed ID: 22038554)
1. Geranylgeranylacetone has anti-hepatitis C virus activity via activation of mTOR in human hepatoma cells.
Takeshita S; Ichikawa T; Taura N; Miyaaki H; Matsuzaki T; Otani M; Muraoka T; Akiyama M; Miuma S; Ozawa E; Ikeda M; Kato N; Isomoto H; Takeshima F; Nakao K
J Gastroenterol; 2012 Feb; 47(2):195-202. PubMed ID: 22038554
[TBL] [Abstract][Full Text] [Related]
2. Insulin-induced mTOR activity exhibits anti-hepatitis C virus activity.
Muraoka T; Ichikawa T; Taura N; Miyaaki H; Takeshita S; Akiyama M; Miuma S; Ozawa E; Isomoto H; Takeshima F; Nakao K
Mol Med Rep; 2012 Feb; 5(2):331-5. PubMed ID: 22052332
[TBL] [Abstract][Full Text] [Related]
3. Geranylgeranylacetone induces antiviral gene expression in human hepatoma cells.
Ichikawa T; Nakao K; Nakata K; Hamasaki K; Takeda Y; Kajiya Y; Higashi S; Ohkubo K; Kato Y; Ishii N; Eguchi K
Biochem Biophys Res Commun; 2001 Jan; 280(3):933-9. PubMed ID: 11162614
[TBL] [Abstract][Full Text] [Related]
4. Interferon-alpha-induced mTOR activation is an anti-hepatitis C virus signal via the phosphatidylinositol 3-kinase-Akt-independent pathway.
Matsumoto A; Ichikawa T; Nakao K; Miyaaki H; Hirano K; Fujimito M; Akiyama M; Miuma S; Ozawa E; Shibata H; Takeshita S; Yamasaki H; Ikeda M; Kato N; Eguchi K
J Gastroenterol; 2009; 44(8):856-63. PubMed ID: 19436942
[TBL] [Abstract][Full Text] [Related]
5. Effect of ethanol on innate antiviral pathways and HCV replication in human liver cells.
Plumlee CR; Lazaro CA; Fausto N; Polyak SJ
Virol J; 2005 Dec; 2():89. PubMed ID: 16324217
[TBL] [Abstract][Full Text] [Related]
6. Anti-ulcer agent teprenone inhibits hepatitis C virus replication: potential treatment for hepatitis C.
Ikeda M; Kawai Y; Mori K; Yano M; Abe K; Nishimura G; Dansako H; Ariumi Y; Wakita T; Yamamoto K; Kato N
Liver Int; 2011 Jul; 31(6):871-80. PubMed ID: 21645219
[TBL] [Abstract][Full Text] [Related]
7. Detection of anti-hepatitis C virus effects of interferon and ribavirin by a sensitive replicon system.
Kato T; Date T; Miyamoto M; Sugiyama M; Tanaka Y; Orito E; Ohno T; Sugihara K; Hasegawa I; Fujiwara K; Ito K; Ozasa A; Mizokami M; Wakita T
J Clin Microbiol; 2005 Nov; 43(11):5679-84. PubMed ID: 16272504
[TBL] [Abstract][Full Text] [Related]
8. ME3738 enhances the effect of interferon and inhibits hepatitis C virus replication both in vitro and in vivo.
Abe H; Imamura M; Hiraga N; Tsuge M; Mitsui F; Kawaoka T; Takahashi S; Ochi H; Maekawa T; Hayes CN; Tateno C; Yoshizato K; Murakami S; Yamashita N; Matsuhira T; Asai K; Chayama K
J Hepatol; 2011 Jul; 55(1):11-8. PubMed ID: 21145867
[TBL] [Abstract][Full Text] [Related]
9. DDX60L Is an Interferon-Stimulated Gene Product Restricting Hepatitis C Virus Replication in Cell Culture.
Grünvogel O; Esser-Nobis K; Reustle A; Schult P; Müller B; Metz P; Trippler M; Windisch MP; Frese M; Binder M; Fackler O; Bartenschlager R; Ruggieri A; Lohmann V
J Virol; 2015 Oct; 89(20):10548-68. PubMed ID: 26269178
[TBL] [Abstract][Full Text] [Related]
10. Double-stranded RNA-activated protein kinase inhibits hepatitis C virus replication but may be not essential in interferon treatment.
Chang JH; Kato N; Muroyama R; Taniguchi H; Guleng B; Dharel N; Shao RX; Tateishi K; Jazag A; Kawabe T; Omata M
Liver Int; 2010 Feb; 30(2):311-8. PubMed ID: 19840259
[TBL] [Abstract][Full Text] [Related]
11. An anti-ulcer drug, geranylgeranylacetone, suppresses inducible nitric oxide synthase in cultured vascular smooth muscle cells.
Yamamoto K; Sarukawa M; Ito T; Aoki H; Ichida M; Shimada K
J Hypertens; 2005 Oct; 23(10):1847-53. PubMed ID: 16148608
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of antiviral activity against hepatitis C virus in vitro by interferon combination therapy.
Okuse C; Rinaudo JA; Farrar K; Wells F; Korba BE
Antiviral Res; 2005 Jan; 65(1):23-34. PubMed ID: 15652968
[TBL] [Abstract][Full Text] [Related]
13. Pegylated IFN-α suppresses hepatitis C virus by promoting the DAPK-mTOR pathway.
Liu WL; Yang HC; Hsu CS; Wang CC; Wang TS; Kao JH; Chen DS
Proc Natl Acad Sci U S A; 2016 Dec; 113(51):14799-14804. PubMed ID: 27930338
[TBL] [Abstract][Full Text] [Related]
14. A functional genomic screen reveals novel host genes that mediate interferon-alpha's effects against hepatitis C virus.
Zhao H; Lin W; Kumthip K; Cheng D; Fusco DN; Hofmann O; Jilg N; Tai AW; Goto K; Zhang L; Hide W; Jang JY; Peng LF; Chung RT
J Hepatol; 2012 Feb; 56(2):326-33. PubMed ID: 21888876
[TBL] [Abstract][Full Text] [Related]
15. Suppressor of cytokine signaling 3 suppresses hepatitis C virus replication in an mTOR-dependent manner.
Shao RX; Zhang L; Peng LF; Sun E; Chung WJ; Jang JY; Tsai WL; Hyppolite G; Chung RT
J Virol; 2010 Jun; 84(12):6060-9. PubMed ID: 20375166
[TBL] [Abstract][Full Text] [Related]
16. The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA.
Zhou S; Liu R; Baroudy BM; Malcolm BA; Reyes GR
Virology; 2003 Jun; 310(2):333-42. PubMed ID: 12781720
[TBL] [Abstract][Full Text] [Related]
17. Novel alpha interferon (IFN-alpha) variant with improved inhibitory activity against hepatitis C virus genotype 1 replication compared to IFN-alpha2b therapy in a subgenomic replicon system.
Escuret V; Martin A; Durantel D; Parent R; Hantz O; Trépo C; Menguy T; Bottius E; Dardy J; Maral J; Escary JL; Zoulim F
Antimicrob Agents Chemother; 2006 Dec; 50(12):3984-91. PubMed ID: 17030563
[TBL] [Abstract][Full Text] [Related]
18. IFN-λ Inhibits MiR-122 Transcription through a Stat3-HNF4α Inflammatory Feedback Loop in an IFN-α Resistant HCV Cell Culture System.
Aboulnasr F; Hazari S; Nayak S; Chandra PK; Panigrahi R; Ferraris P; Chava S; Kurt R; Song K; Dash A; Balart LA; Garry RF; Wu T; Dash S
PLoS One; 2015; 10(12):e0141655. PubMed ID: 26657215
[TBL] [Abstract][Full Text] [Related]
19. Abacavir coadministration does not interfere with the suppressive activity of ribavirin in an HCV replicon system.
Van den Eynde E; Quer J; Cubero M; Curran A; Homs M; Garcia-Cehic D; Falco V; Ribera E; Esteban JI; Pahissa A; Crespo M
Antivir Ther; 2011; 16(6):887-93. PubMed ID: 21900721
[TBL] [Abstract][Full Text] [Related]
20. A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C.
Vrolijk JM; Kaul A; Hansen BE; Lohmann V; Haagmans BL; Schalm SW; Bartenschlager R
J Virol Methods; 2003 Jun; 110(2):201-9. PubMed ID: 12798249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
